miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 426-435

  Sun, Chun Yan ^a   She, Xiao Mei ^a   Qin, You ^a   Chu, Zhang Bo ^a   Chen, Lei ^a   Ai, Li Sha ^a   Zhang, Lu ^a   Hu, Yu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; INTERLEUKIN 6; LUCIFERASE; MICRORNA 15A; MICRORNA 16; SCATTER FACTOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; TUMOR VASCULARIZATION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MICRORNAS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PLASMA CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873564989     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs333     Document Type: Article

References (55)

1. Garzon,R. et al. (2006) MicroRNA expression and function in cancer. Trends Mol. Med., 12, 580-587.
2. He,L. et al. (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet., 5, 522-531.
3. Bartel,D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
4. Mello,C.C. et al. (2004) Micromanaging insulin secretion. Nat. Med., 10, 1297-1298.
5. Baralle,M. et al. (2007) Genetics and molecular biology: micro RNAs are welcome to the lipid field. Curr. Opin. Lipidol., 18, 375-377.
6. Triboulet,R. et al. (2007) Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science, 315, 1579-1582.
7. Calin,G.A. et al. (2006) MicroRNA-cancer connection: the beginning of a new tale. Cancer Res., 66, 7390-7394.
8. Calin,G.A. et al. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer, 6, 857-866.
9. Lu,J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834-838.
10. Blenkiron,C. et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol., 8, R214.
11. Dews,M. et al. (2006) Augmentation of tumor angiogenesis by a Mycactivated microRNA cluster. Nat. Genet., 38, 1060-1065.
12. Lee,D.Y. et al. (2007) MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc. Natl. Acad. Sci. U.S.A., 104, 20350-20355.
13. Barlogie,B. et al. (1997) Biology and therapy of multiple myeloma in 1996. Semin. Hematol., 34(1 Suppl 1), 67-72.
14. Munshi,N.C. et al. (2001) Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin. Oncol., 28, 565-569.
15. Vacca,A. et al. (2001) Bone marrow angiogenesis in patients with active multiple myeloma. Semin. Oncol., 28, 543-550.
16. Giuliani,N. et al. (2004) Angiogenic switch in multiple myeloma. Hematology, 9, 377-381.
17. Ria,R. et al. (2003) Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia, 17, 1961-1966.
18. Kumar,S. et al. (2003) Expression of VEGF and its receptors by myeloma cells. Leukemia, 17, 2025-2031.
19. Dankbar,B. et al. (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood, 95, 2630-2636.
20. Iwasaki,T. et al. (2002) Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br. J. Haematol., 116, 796-802.
21. Di Raimondo,F. et al. (2000) Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica, 85, 800-805.
22. Podar,K. et al. (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood, 98, 428-435.
23. Podar,K. et al. (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood, 105, 1383-1395.
24. Hua,Z. et al. (2006) MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE, 1, e116.
25. Roccaro,A.M. et al. (2009) MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood, 113, 6669-6680.
26. Sun,C.Y. et al. (2010) Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling. Tumour Biol., 31, 121-128.
27. Sun,C. et al. (2009) The effect of brain-derived neurotrophic factor on angiogenesis. J. Huazhong Univ. Sci. Technol. Med. Sci., 29, 139-143.
28. Hu,Y. et al. (2007) Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma. Cancer Genet. Cytogenet., 178, 1-10.
29. Calin,G.A. et al. (2008) MiR-15a and miR-16-1 cluster functions in human leukemia. Proc. Natl. Acad. Sci. U.S.A., 105, 5166-5171.
30. Cimmino,A. et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U.S.A., 102, 13944-13949.
31. Xu,J.L. et al. (2002) Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J. Clin. Pathol., 55, 530-534.
32. Lewis,B.P. et al. (2003) Prediction of mammalian microRNA targets. Cell, 115, 787-798.
33. Betel,D. et al. (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res., 36, D149-D153.
34. Nielsen,C.B. et al. (2007) Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA, 13, 1894-1910.
35. Finnerty,J.R. et al. (2010) The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J. Mol. Biol., 402, 491-509.
36. Visone,R. et al. (2009) MiRNAs and cancer. Am. J. Pathol., 174, 1131-1138.
37. Esquela-Kerscher,A. et al. (2006) Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer, 6, 259-269.
38. Calin,G.A. et al. (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A., 99, 15524-15529.
39. Urbich,C. et al. (2008) Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc. Res., 79, 581-588.
40. Fish,J.E. et al. (2009) MicroRNAs: opening a new vein in angiogenesis research. Sci. Signal., 2, pe1.
41. Wu,F. et al. (2009) Role of specific microRNAs for endothelial function and angiogenesis. Biochem. Biophys. Res. Commun., 386, 549-553.
42. Löffler,D. et al. (2007) Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood, 110, 1330-1333.
43. Pichiorri,F. et al. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. U.S.A., 105, 12885-12890.
44. Liu,B. et al. (2009) MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer, 66, 169-175.
45. Mishra,P.J. et al. (2009) MicroRNA reexpression as differentiation therapy in cancer. J. Clin. Invest., 119, 2119-2123.
46. Trang,P. et al. (2011) Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther., 19, 1116-1122.
47. Liu,C. et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med., 17, 211-215.
48. Kota,J. et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137, 1005-1017.
49. Bonci,D. et al. (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med., 14, 1271-1277.
50. Bandi,N. et al. (2009) miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res., 69, 5553-5559.
51. Wang,X. et al. (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE, 3, e2557.
52. Roldo,C. et al. (2006) MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol., 24, 4677-4684.
53. Liu,L. et al. (2010) microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem. Biophys. Res. Commun., 400, 236-240.
54. Wu,H. et al. (2009) Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res., 19, 439-448.
55. Corthals,S.L. et al. (2010) Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk. Res., 34, 677-681.